Oss, September, 14th, 2015 – NTRC today announced that it has extended its bioinformatics analysis to its Oncolines™ cancer cell line profiling service. OncolinesProfiler™ involves the comparison of a clients’ compound against more than 100 pre-profiled therapeutics in cell proliferation assays. The new service is ideally suited for comparative analyses of new candidate molecules with established drugs; to identify the mechanism of action of lead compounds identified in phenotypic screens; or for drug repurposing.
OncolinesProfiler™ makes use of NTRC’s database of cancer cell line profiles of more than hundred therapeutics, including all standard-of-care cytotoxics, almost all approved targeted agents and many investigational drugs, including kinase inhibitors, epigenetic modulators, Bcl2 inhibitors, and several compounds with unique mechanisms of actions.
Clients of NTRC’s OncolinesProfiler™ service receive a report with a number of visual representations of the comparative analysis of their compound(s), a clearly written methods section, and an overview table, summarizing the relative rank and significance of observed correlations. For more information, send an e-mail to firstname.lastname@example.org.
NTRC is a precision medicine company dedicated to the development of new anti-cancer drugs. NTRC facilitates the development of novel therapies by providing cancer cell line profiling services (Oncolines™, SynergyFinder™ and OncolinesProfiler™) and developing new enabling technologies, such as NFK GreenScreen™. In addition, NTRC develops its own novel targeted therapies based on small molecules, such as selective inhibitors of the TTK (Mps1) protein kinase for chromosomally unstable tumors and inhibitors of the tryptophan metabolizing enzymes IDO1 and TDO for cancer immunotherapy.